ArticlePloS one2016
Melatonin Receptor Agonists as the "Perioceutics" Agents for Periodontal Disease through Modulation of Porphyromonas gingivalis Virulence and Inflammatory Response.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Does the association of prostate cancer with night-shift work differ according to rotating vs. fixed schedule? A systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2018Pooled it
- Evaluation of melatonin gel as local drug delivery system for the treatment of periodontitis: a split-mouth randomized controlled trial.BMC oral health · 2025Trial
- Multifunctional dual drug-loaded Gel-Alg/MINO/MEL composite hydrogel for combating three-dimensional multi-species biofilm and experimental periodontitis treatment.Clinical oral investigations · 2026Article
- Effect of Drynaria rhizome in-situ gel in periodontitis management.Bioinformation · 2026Article
- Sleep and circadian disruption reshape immune homeostasis in oral tissues: mechanistic roles of melatonin and cortisol in periodontal disease and xerostomia.Frontiers in immunology · 2026Review
- Rationalization Progress of Novel Drug Delivery System for Intra-periodontal Pockets Against Periodontitis.Pharmaceutical nanotechnology · 2026Review
- Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease.Bioengineering & translational medicine · 2025Article
- Article
- Impact of oral pathogens on inflammatory mediator expression in oral cells.Bioinformation · 2025Article
- Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibitingFrontiers in microbiology · 2025Article
- An unidentified yet notable modification onFASEB bioAdvances · 2024Article
- Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Role of Melatonin in Periodontal Diseases: A Structured Review.Advanced biomedical research · 2024Review
- Beneficial Effects of Melatonin on Periodontitis Management: Far More Than Oral Cavity.International journal of molecular sciences · 2022Review
- Osteoporosis and Alveolar Bone Health in Periodontitis Niche: A Predisposing Factors-Centered Review.Cells · 2022Review
- Anti-biofilm activities of coumarin as quorum sensing inhibitor forJournal of oral microbiology · 2022Article
- Correlation between melatonin concentration and cytokines in cervical mucus in positive samples for the presence of human papillomavirus.Cancer immunology, immunotherapy : CII · 2021Article
- The RagA and RagB proteins of Porphyromonas gingivalis.Molecular oral microbiology · 2021Review
- Quercetin inhibits virulence properties of Porphyromas gingivalis in periodontal disease.Scientific reports · 2020Article
- In Vitro Evaluation of the Antimicrobial and Immunomodulatory Activity of Culinary Herb Essential Oils as Potential Perioceutics.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim"Perioceutics" including antimicrobial therapy and host modulatory therapy has emerged as a vital adjunctive treatment of periodontal disease. Melatonin level was significantly reduced in patients with periodontal diseases suggesting melatonin could be applied as a potential "perioceutics" treatment of periodontal diseases. This study aims to investigate the effects of melatonin receptor agonists (melatonin and ramelteon) on Porphyromonas gingivalis virulence and Porphyromonas gingivalis-derived lipopolysaccharide (Pg-LPS)-induced inflammation.
methodsEffects of melatonin receptor agonists on Porphyromonas gingivalis planktonic cultures were determined by microplate dilution assays. Formation, reduction, and viability of Porphyromonas gingivalis biofilms were detected by crystal violet staining and MTT assays, respectively. Meanwhile, biofilms formation was also observed by confocal laser scanning microscopy (CLSM). The effects on gingipains and hemolytic activities of Porphyromonas gingivalis were evaluated using chromogenic peptides and sheep erythrocytes. The mRNA expression of virulence and iron/heme utilization was assessed using RT-PCR. In addition, cell viability of melatonin receptor agonists on human gingival fibroblasts (HGFs) was evaluated by MTT assays. After pretreatment of melatonin receptor agonists, HGFs were stimulated with Pg-LPS and then release of cytokines (IL-6 and lL-8) was measured by enzyme-linked immunosorbent assay (ELISA).
resultsMelatonin and ramelteon did exhibit antimicrobial effects against planktonic culture. Importantly, they inhibited biofilm formation, reduced the established biofilms, and decreased biofilm viability of Porphyromonas gingivalis. Furthermore, they at sub-minimum inhibitory concentration (sub-MIC) concentrations markedly inhibited the proteinase activities of gingipains and hemolysis in a dose-dependent manner. They at sub-MIC concentrations significantly inhibited the mRNA expression of virulence factors (kgp, rgpA, rgpB, hagA, and ragA), while increasing the mRNA expression of ferritin (ftn) or hemolysin (hem). They did not show obvious cytotoxicity toward HGFs. They inhibited Pg-LPS-induced IL-6 and IL-8 secretion, which was reversed by luzindole, the melatonin receptor antagonist.
conclusionMelatonin receptor agonists can inhibit planktonic and biofilm growth of Porphyromonas gingivalis by affecting the virulent properties, as well as Pg-LPS-induced inflammatory response. Our study provides new evidence that melatonin receptor agonists might be useful as novel "perioceutics" agents to prevent and treat Porphyromonas gingivalis-associated periodontal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.